Short Interest in Fidelity Disruptive Medicine ETF (NASDAQ:FMED) Increases Significantly

As of February 28, 2025, the Fidelity Disruptive Medicine ETF (NASDAQ:FMED – Get Free Report) saw a notable rise in its short interest. The total short interest reached 900 shares, marking a substantial increase of 125.0% compared to the total of 400 shares recorded on February 13. This amount represents approximately 0.0% of the ETF's overall shares sold short. Given the ETF's average daily trading volume of 5,700 shares, the current short-interest ratio stands at 0.2 days.

Recent Institutional Activity

In recent reports, Jane Street Group LLC, an institutional investor, significantly increased its stake in the Fidelity Disruptive Medicine ETF. According to its latest 13F filing with the Securities and Exchange Commission, Jane Street Group raised its position by 200.4% during the third quarter. This increase brought their total holdings to 61,342 shares after they purchased an additional 40,924 shares. At the conclusion of the last reporting period, Jane Street Group LLC owned around 2.92% of FMED, with a total value of approximately $1,613,000.

Current Stock Performance

The Fidelity Disruptive Medicine ETF opened at $24.03 on the last trading day. Over the past year, the stock has experienced a low of $23.32 and a high of $26.79. The fund's fifty-day simple moving average is currently at $25.50, while the 200-day simple moving average is at $25.70. FMED has a market capitalization of $50.46 million, a price-to-earnings (P/E) ratio of 42.34, and a beta of 0.94, indicating a relatively stable performance compared to the market.

Dividend Increase

Furthermore, the Fidelity Disruptive Medicine ETF has announced an increase in its quarterly dividend. The recent dividend payment, made on December 24, was $0.112 for shareholders on record as of December 20. This revised dividend translates to an annualized payout of $0.45 and a dividend yield of 1.86%. This indicates a positive shift from the prior quarterly dividend, which was $0.00.

About Fidelity Disruptive Medicine ETF

The Fidelity Disruptive Medicine ETF (FMED) is an actively managed exchange-traded fund focused primarily on healthcare equities. The fund seeks to invest in companies that are driving disruptive innovation within the healthcare sector. Launched on April 16, 2020, FMED is managed by Fidelity.

ETF, Investment, Stocks